Trader notes, earnings previews, Confluences, weekly digests and roundups — long-form analysis grounded in ORTEX short interest, options flow and analyst data.
Trader Note — 15010 total
BWIN enters the back half of the year with an unusual tension at its core: a 37% one-month rally that has pulled shorts back and flipped options sentiment decisively bullish, yet the stock still carries 18% of its…
Beam Therapeutics enters the second week of July with a sharp price rally colliding head-on with one of the heaviest short positions in the gene-editing space. The stock closed at $37.92 on Tuesday, up 10.5% on the…
Revolution Medicines is trading at $190.46 — up 28% over the past month and now within touching distance of the Street's mean price target — creating a fresh question about whether the re-rating has run its course or…
BNTX heads into the week with a fresh analyst target cut from its most prominent sell-side backer — yet the options market is, unusually, leaning more bullish than it has in months. Morgan Stanley's Terence Flynn…
10x Genomics sits in a rare and uncomfortable spot — the Street is rushing to lift price targets while short interest continues to grind higher, and the stock fell 5.4% on Tuesday to $37.83, still below where most of…
Kura Sushi USA has delivered its earnings print — and the Street's response has been a wave of target cuts, sending the stock down 8% on the week to $52.90. The analyst reaction is the clearest signal this week. Every…
CrowdStrike enters the second week of July with a genuinely unusual combination: short interest climbing at its fastest pace in months, a Street that remains broadly bullish but is rapidly resetting price targets…
Parsons Corporation heads into its July 29 earnings with an unusual setup: insiders spent May buying aggressively into weakness while short sellers have been steadily rebuilding positions through June and into…
Palomar Holdings enters the week of July 8 having just posted one of its sharpest short-term rallies in recent memory — up 15% on the week and 34% over the past month — while the Street's most active analyst raises his…
PINS heads into its August 4 earnings with short sellers quietly trimming positions and two analyst actions this week pointing in the same direction — up. The positioning picture has shifted meaningfully over the past…
LEVI has reported Q2 2026 results, and the week's most interesting question is how the dust settles — shorts have already covered aggressively into the print, analysts raised targets in unison beforehand, yet the stock…
LYFT has climbed 5.7% over the past week to $15.44, yet short sellers are simultaneously adding to positions — a divergence that sets up an interesting tension heading into the August 7 earnings print. The short side…
Avantor enters its July 29 earnings with a notable divergence: analysts are lifting price targets at a faster pace than at any point this year, yet short sellers have quietly rebuilt positions by more than 20% over the…
DELL pulled back 3.3% on the week to $417.28, but the more interesting development is in the options market, where a sharp rotation away from defensive positioning marks one of the most significant sentiment shifts of…
TOST enters the week with a striking divergence: the stock is up 20% over the past month and 6% in the last five days, yet short sellers have been aggressively adding positions into the rally. Short interest is the…
Moderna has now rallied 68% in a month to $79.77 — yet the Street's price targets remain well below the current price, and 15.6% of the free float is still short. The analyst picture this week captures the tension…
CI has quietly recovered 4% this week to $286.62, yet the more striking shift is in how options traders are now positioned — moving from defensive hedging to the most call-heavy stance in nearly a year. The options…
Bloom Energy dropped nearly 11% on the week to $269.57 — sliding back below the mean analyst price target of $282 that the stock had been trading above, and doing so with Q2 results just three weeks away. The price…
Crinetics Pharmaceuticals heads into the week with its stock having nearly doubled on a massive catalyst — while Wall Street responds by downgrading in unison, creating one of the more striking divergences in recent…
ESTA enters the week with an interesting split: the stock has rallied 22% over the past month and Citigroup just lifted its price target by $16, yet short sellers have quietly rebuilt positions to a level well above…
